Dr. Neil Dwayne Gross, MD

Dr. Gross practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Gross' NPI, 1841208378, was assigned on August 3, 2006. Dr. Gross graduated from OHSU School of Medicine in 1998. Dr. Gross holds Texas license Q1156.

Dr. Gross' primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Gross' primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gross practices. Vendor and product names are available with a free account.

Otolaryngology is Dr. Gross' primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Gross is board certified in otolaryngology by the ACGME. Dmand AI has Dr. Gross' licenses on file in 5 states: Texas, Florida, Oregon, Oklahoma and New York.

Dmand AI lists larynx and vocal cord disease and thyroid surgery among the conditions Dr. Gross treats.

CMS data shows 361 Medicare services from Dr. Gross across 8 procedure codes in 2024, for 219 Medicare patients. Medicare paid $40,912 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 219 Medicare patients who saw Dr. Gross in 2024. The largest group is 65 to 74, with 122 patients. 75% of them have high blood pressure, and 74% have high cholesterol. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gross' median patient age at 72, with 30% women.

In 2024, Dr. Gross wrote 32 Medicare Part D claims for 17 patients. 94% of them were for generic drugs. CMS names the drug for 16 of them, across 1 drug with 11 or more claims each, at $137 in total drug cost. In 2017, CMS named 26 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Gross for performance year 2024, reported as part of a group. Dr. Gross accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gross as offering telehealth. CMS counts 18 procedures of melanoma (skin cancer) excision by Dr. Gross, more than 73% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 218 papers to Dr. Gross, published from 2005 to 2025. 2020 was the busiest year, with 21. The most frequent topics are Carcinoma, Squamous Cell, Head and Neck Neoplasms and Oropharyngeal Neoplasms. Dr. Gross has published most often in Head Neck. Dr. Gross' most frequent co-authors are Renata Ferrarotto, MD, Ryan Patrick Goepfert, MD and Mark Edwin Zafereo, MD.

Dmand AI links Dr. Gross to 5 clinical trials. 3 are still active or recruiting. Conditions studied include Carcinoma, Transitional Cell, Mouth Neoplasms and Squamous Cell Carcinoma of Head and Neck. M.D. Anderson Cancer Center sponsors the most, 2.

CMS Open Payments shows 116 general payments to Dr. Gross from 8 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 50% of the total. Intuitive Surgical, Inc. paid the most, $30,410. It also lists 18 research payments totaling $3,473 from 2022 to 2025.

Dmand AI lists 22 awards for Dr. Gross, most recently Albert and Elaine Borchard Foundation Award in 2014.

Dr. Gross graduated from OHSU School of Medicine in 1998.

Dr. Gross is in network with 5 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.